Regenerative Pathway for Type 2 Diabetes

Pathway overview

Public reporting describes an umbilical-cord mesenchymal stem-cell clinical translation/application pathway for type 2 diabetes. This does not replace established diabetes care. Any assessment must consider residual beta-cell function, metabolic control, complications and overall health.

Information likely required for review

• Confirmed diabetes type and duration
• Recent HbA1c and fasting glucose
• C-peptide and insulin data where available
• Current medications and insulin regimen
• BMI and weight history
• Kidney and liver function
• Cardiovascular, eye, nerve or kidney complications
• History of cancer, infection or immune disease

What happens after submission

1. RMC checks the case summary and missing records.
2. Where a credible route exists, the case is prepared for an appropriate medical institution.
3. The hospital decides whether consultation, further testing or in-person assessment is warranted.
4. A formal plan and fee structure, if applicable, should come after medical review.

Evidence and limitations

Cell and regenerative therapies may have condition-specific evidence, eligibility rules, risks and uncertainties. Results from a study population do not predict an individual outcome. Standard treatment options should also be discussed with a qualified physician.

Public sources used for pathway identification

• Hainan government — frontier biomedical projectsOfficial public reporting identifying a type 2 diabetes clinical translation/application project.
• National biomedical new-technology frameworkNational rules distinguishing research from clinical translation and application.